Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.30.2 (
endonuclease
)
18,621
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CpG
endonuclease
activity was identified in nuclear extracts obtained from mouse lung tumors. Enzyme activity was determined using a 333 bp polymerase chain reaction product of the estrogen receptor-alpha gene that contained either radiolabeled cytosine or tritium-labeled methyl groups at CpG sites. Activity was measured as the release of radioactivity from the substrate. The product of the nuclease activity was identified by high pressure liquid chromatography (HPLC) as either 5-methyl-2'-deoxycytidine when the CpG sites in the substrate were methylated or 2'-deoxycytidine when the CpG sites were not methylated. The CpG
endonuclease
activity was dependent on nuclear protein and temperature, had a proclivity for double-stranded over single-stranded DNA and was inhibited by ethylenediaminetetraacetic acid or 2-mercaptoethanol. Strain A/J mouse lung tumors induced by vinyl carbamate had a greater level of CpG
endonuclease
activity than non-involved lung tissue.
Budesonide
, a potent chemopreventive agent in mouse lung, not only prevented an increase in CpG
endonuclease
activity in lung tumors but, when administered to mice with established tumors, also decreased the level of
endonuclease
activity in the tumors. The effect of budesonide on CpG
endonuclease
activity in lung tumors was inversely related to its published effect on DNA methylation in mouse lung tumors, i.e. the drug decreased CpG
endonuclease
activity and increased the methylation of DNA. The increased CpG
endonuclease
activity in mouse lung tumors and its inhibition by budesonide would suggest this
endonuclease
as a potential molecular target for chemoprevention.
...
PMID:Modulation by budesonide of a CpG endonuclease in mouse lung tumors. 1736 Oct 11